Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, c
Dr Rebecca Power, Postdoctoral Researcher at the Nutrition Research Centre Ireland, shared the role that CANTAB played in her latest publication: Targeted Nutritional Intervention for Patients with Mild Cognitive Impairment: The Cognitive impAiRmEnt Study (CARES) Trial 1
Industry experts working at the forefront of drug development, devices and digital health shared their lessons learned delivering virtual trials during the Covid-19 pandemic at Cambridge Cognition’s fourth annual Digital Health Event. Catch up on the key takeways from this thought-leading discussion.
Automated administration of Serial Subtraction in a remote data collection context: novel timing fea
New research presented at CTAD 2020 reports the successful derivation of novel measures of timing for a more nuanced assessment of performance on the Serial Subtraction task.
The volume of discussion and questions during our recent webinar: Remote Cognitive Testing and Lessons Learned During Lockdown was great to see. Unfortunately we were unable to answer all the questions in the time we had so Dr Caroline Skirrow has put together a Q and A addressing some of the key themes raised.
CANTAB Research Grant assists research into defining cognitive phenotypes in individuals with CNVs a
Ciara Molloy recently spoke to us about the impact that receiving one of the three 2020 CANTAB Research Grant prizes will have on her research: ‘The impact of rare copy number variants on cognition: Defining cognitive phenotypes in individuals with CNVs associated with neurodevelopmental and neuropsychiatric disorders.’
2020 CANTAB Research Grant supports research into combined dexmedetomidine / ketamine nasal spray fo
The winner of one of the three 2020 CANTAB Research Grant prizes, Dr Amie Hayley, Swinburne University of Technology explains the impact CANTAB will have on her research: Combined dexmedetomidine/ketamine nasal spray for analgesia: a pilot feasibility and efficacy trial.
Dr Simone De Luca recently received the 2020 CANTAB Research Grant primary award for her project: “New ways to assess vascular cognitive impairment and dementia (VCID) in chronic lung disease”. We spoke to her about the impact winning would have on her research.
Using CANTAB to study the relationships between executive function, eating behavior and preoperative
PhD candidate Gro Walø-Syversen of Oslo University Hospital, shared the role that CANTAB played in her latest publication: Executive Function, Eating Behavior, and Preoperative Weight Loss in Bariatric Surgery Candidates: An Observational Study.
Alexander Friend shares the role CANTAB played in the research he conducted on cognitive impairment at high-altitude while at The University of Birmingham.
At the virtual AAIC 2020 conference Dr Francesca Cormack shared her research, focusing on automatic speech recognition for verbal cognitive testing.
At the virtual AAIC 2020 conference Dr Elizabeth Baker presented data on the successful delivery of CANTABTM assessments across diverse health systems and ages: 10 – 90 years old.
The study captures normative performance across the lifespan to support a cognitive screening tool for characterising a range of neuropsychological disorders in clinics across India.
Older adults shoulder a disproportionate burden of chronic diseases and consumption of prescription drugs. Nevertheless, older adults, especially those aged over 75 years, are chronically under-represented in clinical trials. In this two part series, Dr Kiri Granger explores the risks of under-presentation and outlines guidance for including older adults in clinical trials.
Read on for session two: key design considerations when including elderly patients in clinical trials, with a focus on cognitive assessment.
We caught up with Jana Thomas of Radboud University Medical Centre to find out more about the bidirectional relationship between poor sleep and Alzheimer’s disease.
Examination of the neural basis of psychotic-like experiences in adolescence during processing of em
We caught up with Dr Evan Papanastasiou from King's College London to find out why he chose CANTAB to examine the neural basis of psychotic-like experiences in adolescence during processing of emotional faces.
Despite chemotherapy-associated cognitive impairment (CACI, aka chemobrain) affecting 75% of all cancer survivors, little is understood about the mechanisms underlying the disorder. In efforts to address this research gap, Prof Alexandre Chan from the University of California, Irvine used CANTAB to conduct an evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment. Read on to find out the results.
We caught up with Lydia Devenney from Letterkenny Institute of Technology to find out why she chose CANTAB to assist her research into investigating attention, memory functioning, and mood in a natural setting with real‐life alcohol consumption levels.
What is the impact of stress and environment on executive function and motivation for primary school
We caught up with Toby Bartle, Registered Psychologist and PhD Candidate at James Cook University, to find out why he chose CANTAB when looking at the impact of stress and environment on executive function and motivation for primary school children.
We caught up with University of Ulster researcher, Kyle Wallace, to find out why he chose CANTAB to investigate the links between cognitive function, hydration status and martial arts.
We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.
Comprehensive neuropsychological testing typically takes hours to complete, which can be mentally and physically burdensome for patients. Furthermore, the travel required and overall time-commitment to undergo these procedures within a clinic can result in decreased study compliance. Together these factors can confound conclusions concerning treatment efficacy. Here we will discuss how digital health can reduce these burdens when implementing therapeutic interventions to improve patient outcomes.
Mental health researcher at the University of Sydney: Brain and Mind Centre, Ashleigh Tickell, recently submitted her PhD on the feasibility of cognitive screening as standard clinical care in a young adult mental health unit. We caught up with Ashleigh to find out the outcomes of using CANTAB for her project.
We are pleased to announce our partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.
We’re delighted to announce a new $0.5m contract with a major pharmaceutical company for the use of our Cognition Kit digital health software in a clinical trial.
Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.
Exciting new research shows not only that web-based cognitive assessments are suitable for older adults but, for many, computerised assessments are actually preferable to traditional pen-and-paper tasks.
At the 2017 International CNS Summit in Boca Raton, Florida, we were pleased to release the positive results from a pilot study into the evaluation of cognition and mood using wearable technology in patients with MDD.
Cambridge Cognition are attending the Collaborating for Novel Solutions (CNS) Summit: 16th-19th November 2017.
We’re pleased to announce that Hogrefe Psykologien Kustannus Oy is now an exclusive distributor of CANTAB software products for use in Finland by academic researchers and healthcare professionals.
Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?
Winner of the 2016 Global Prize for the CANTAB Research Grant, Toni McCrossin, Clinical Officer for the New South Wales Brain Tissue Resource Centre (NSWBTRC) explains how access to CANTAB cognitive assessments are supporting their project.